Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy
- PMID: 18417840
- PMCID: PMC2636113
- DOI: 10.4103/0301-4738.40380
Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy
References
-
- Siqueira RC, Costa RA, Scott IU, Cintra LP, Jorge R. Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy. Acta Ophthalmol Scand. 2006;84:834–5. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
